Achievement of treatment targets among patients with type 2 diabetes in 2015 and 2020 in Canadian primary care
Canadian Medical Association Journal · 09.01.2023 · 195 (1) · E1-E9
DOI: 10.1503/cmaj.220673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Medical Association Journal, online erschienen am 08.01.2023. Verfasst von Shiva Nandiwada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine (Nandiwada, Yeung, Lau) and of Family Medicine (Manca), University of Alberta, Edmonton, Alta. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Medicine (Nandiwada, Yeung, Lau) and of Family Medicine (Manca), University of Alberta, Edmonton, Alta.
- Departments of Medicine (Nandiwada, Yeung, Lau) and of Family Medicine (Manca), University of Alberta, Edmonton, Alta. darren.lau@ualberta.ca.
Zitieren
APA
Nandiwada, S., Manca, D. P., Yeung, R. O., & Lau, D. (2023). Achievement of treatment targets among patients with type 2 diabetes in 2015 and 2020 in Canadian primary care. Canadian Medical Association Journal, 195(1), E1-E9. https://doi.org/10.1503/cmaj.220673
Vancouver
Nandiwada S, Manca DP, Yeung RO, Lau D. Achievement of treatment targets among patients with type 2 diabetes in 2015 and 2020 in Canadian primary care. Canadian Medical Association Journal. 2023;195(1):E1-E9. doi:10.1503/cmaj.220673
BibTeX
@article{Nandiwada2023,
author = {Nandiwada, Shiva and Manca, Donna P and Yeung, Roseanne O and Lau, Darren},
title = {Achievement of treatment targets among patients with type 2 diabetes in 2015 and 2020 in Canadian primary care},
journal = {Canadian Medical Association Journal},
year = {2023},
volume = {195},
number = {1},
pages = {E1--E9},
doi = {10.1503/cmaj.220673}
}
EUVIMED